In vivo action of novel alkyl methyl quinolone alkaloids against Helicobacter pylori

Journal of Antimicrobial Chemotherapy

Volumn 50, Issue 4, 2002, Pages 547-552

  Tominaga, Kazunari ^a   Higuchi, Kazuhide ^a   Hamasaki, Norio ^a   Hamaguchi, Masaki ^a   Takashima, Takashi ^a   Tanigawa, Tetsuya ^a   Watanabe, Toshio ^a   Fujiwara, Yasuhiro ^a   Tezuka, Yasuhiro ^b   Nagaoka, Takema ^b   Kadota, Shigetoshi ^b   Ishii, Eiji ^c   Kobayashi, Kazuo ^a   Arakawa, Tetsuo ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

^c OSAKA CITY INSTITUTE OF PUBLIC HEALTH AND ENVIRONMENTAL SCIENCES   (Japan)

Author keywords

Alkyl methyl quinolones; Eradication; H. pylori; Respiration

Indexed keywords

ALKALOID DERIVATIVE; MYELOPEROXIDASE; OMEPRAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVITY; ERADICATION THERAPY; GERBIL; HELICOBACTER INFECTION; HELICOBACTER PYLORI; IN VIVO STUDY; NONHUMAN; STOMACH;

EID: 0036800215     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkf159     Document Type: Article

References (30)

1. Blaser, M. J. (1987). Gastric Campylobacter-like organisms, gastritis, and peptic ulcer disease. Gastroenterology 93, 371-83.
2. Marshall, B. J., Armstrong, J. A., McGechie, D. B. & Glancy, R. J. (1985). Attempt to fulfill Koch's postulates for pyloric Campylobacter. Medical Journal of Australia 142, 436-9.
3. Parsonnet, J., Friedman, G. D., Vandersteen, D. P., Chang, Y., Vogelman, J. H., Orentreich, N. et al. (1991). Helicobacter pylori infection and the risk of gastric carcinoma. New England Journal of Medicine 325, 1127-31.
4. Chiba, N., Rao, B. V., Rademaker, J. W. & Hunt, R. H. (1992). Meta-analysis of antibiotic therapy in eradicating Helicobacter pylori. American Journal of Gastroenterology 87, 1716-27.
5. Marshall, B. J., Goodwin, C. S., Warren, J. R., Murray, R., Blincow, E. D., Blackbourn, S. J. et al. (1988). Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet ii, 1437-42.
6. Rauws, E. A. J. & Tytgat, G. N. J. (1990). Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet 335, 1233-5.
7. Adamek, R. J., Suerbaum, S., Pfaffenbach, B. & Opferkuch, W. (1998). Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin-influence on treatment outcome. American Journal of Gastroenterology 93, 386-9.
8. Alarcón, T., Domingo, D., Prieto, N. & López-Brea, M. (2000). Clarithromycin resistance stability in Helicobacter pylori: influence of the MIC and type of mutation in the 23S rRNA. Journal of Antimicrobial Chemotherapy 46, 613-6.
9. Higuchi, K., Arakawa, T., Ando, K., Fujiwara, Y., Uchida, T. & Kuroki, T. (1999). Eradication of Helicobacter pylori with a Chinese herbal medicine without emergence of resistant colonies. American Journal of Gastroenterology 94, 1419-20.
10. Ishii, E. (1997). Genus Helicobacter pylori in stomach and antibacterial activity of natural materials against Helicobacter pylori. Gastroenterological Seminars 68, 143-52.
11. Hamasaki, N., Ishii, E., Tominaga, K., Tezuka, Y., Nagaoka, K., Kadota, S. et al. (2000). Highly selective antibacterial activity of novel alkyl quinolone alkaloids from a Chinese herbal medicine, Gosyuyu (Wu-Chu-Yu), against Helicobacter pylori in vitro. Microbiology and Immunology 44, 9-15.
12. Nishikawa, M., Sato, E. F., Utsumi, K. & Inoue, M. (1996). Oxygen-dependent regulation of energy metabolism in ascites tumor cells by nitric oxide. Cancer Research 56, 4535-40.
13. Bradley, P. P., Christensen, R. D. & Rothstein, G. (1982). Cellular and extracellular myeloperoxidase in pyogenic inflammation. Blood 60, 618-22.
14. McNulty, C. A. M. (1989). Treatment of Campylobacter pylori infection: Microbiological viewpoint. In Campylobacter pylori in Gastritis and Peptic Ulcer Disease (Blaser, M. J., Ed.), pp. 195-207. Igaku-shoin, New York, NY, USA.
15. Dixon, M. F., Genta, R. M., Yardley, J. H. & Correa, P. (1996). Classification and grading of gastritis. The updated Sydney System. American Journal of Surgical Pathology 20, 1161-81.
16. Nagata, K., Tsukita, S., Tamura, T. & Sone, N. (1996). A cb-type cytochrome-c oxidase terminates the respiratory chain in Helicobacter pylori. Microbiology 142, 1757-63.
17. Moss, C. W., Lambert-Fair, M. A., Nicholson, M. A. & Guerrant, G. O. (1990). Isoprenoid quinones of Campylobacter cryaerophilia, C. cinaedi, C. fennelliae, C. hyointestinalis, C. pylori, and 'C. upsaliensis'. Journal of Clinical Microbiology 28, 395-7.
18. Tominaga, K., Hamasaki, N., Watanabe, T., Uchida, T., Fujiwara, Y., Takaishi, O. et al. (1999). Effect of culture conditions on morphological changes of Helicobacter pylori. Journal of Gastroenterology 34, Suppl., 28-31.
19. Nakamura, A., Park, A. M., Nagata, K., Sato, E. F., Kashiba, M., Tamura, T. et al. (2000). Oxidative cellular damage associated with transformation of Helicobacter pylori from a bacillary to a coccoid form. Free Radical Biology and Medicine 28, 1611-8.
20. Dekker, K. A., Inagaki, T., Gootz, T. D., Huang, L. H., Kojima, Y., Kohlbrenner, W. E. et al. (1998). New quinolone compounds from Pseudonocardia sp. with selective and potent anti-Helicobacter pylori activity: Taxonomy of producing strains, fermentation, isolation, structural eradication and biological activities. Journal of Antibiotics 51, 145-52.
21. Kunze, B., Hofle, G. & Reichenbach, H. (1987). The aurachins, new quinolone antibiotics from myxobacteria: production, physicochemical and biological properties. Journal of Antibiotics 40, 258-65.
22. Drica, K. & Zhao, X. (1997). DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiology and Molecular Biology Reviews 61, 377-92.
23. Khodursky, A. B. & Cozzarelli, N. R. (1998). The mechanism of inhibition of topoisomerase IV by quinolone antibacterials. Journal of Biological Chemistry 273, 27668-77.
24. Nagata, K., Satoh, H., Iwahi, T., Shimoyama, T. & Tamura, T. (1993). Potent inhibitory action of the gastric proton pump inhibitor lansoprazole against urease activity of Helicobacter pylori: unique action selective for H. pylori cells. Antimicrobial Agents and Chemotherapy 37, 769-74.
25. Nakamura, H., Yoshiyama, H., Takeuchi, H., Mizote, T., Okita, K. & Nakazawa, T. (1998). Urease plays an important role in the chemotactic motility of Helicobacter pylori in a viscous environment. Infection and Immunity 66, 4832-7.
26. Keto, Y., Takahashi, S. & Okabe, S. (1999). Healing of Helicobacter pylori-induced gastric ulcers in Mongolian gerbils. Digestive Diseases and Sciences 44, 257-65.
27. Kusuhara, H., Hirayama, F., Matsuyuki, H., Hisadome, M. & Ikeda, Y. (1998). Evaluation of combined antibiotic-omeprazole therapies in Helicobacter pylori-infected Mongolian gerbils. Journal of Gastroenterology 33, 14-7.
28. Nagata, K., Hirai, K., Koyama, J., Wada, Y. & Tamura, T. (1998). Antimicrobial activity of novel furanonaphthoquinone analogs. Antimicrobial Agents and Chemotherapy 42, 700-2.
29. Carbone, M., Fera, M. T., Cecchetti, V., Tabarrini, O., Losi, E., Cusumano, V. et al. (1997). In vitro activities of new quinolones against Helicobacter pylori. Antimicrobial Agents and Chemotherapy 41, 2790-2.
30. Fung-Tomc, J., Minassian, B., Kolek, B., Washo, T., Huczko, E. & Bonner, D. (2000). In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinone, gatifloxacin. Journal of Antimicrobial Chemotherapy 45, 437-46.